{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=33", "query": { "intervention": "serum sample", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 8371, "total_pages": 838, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T09:53:51.357Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04200963", "title": "A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Carcinoma Bladder", "Bladder Cancer", "Bladder Disease", "Solid Tumor", "Solid Carcinoma", "Solid Tumor, Adult", "Metastatic Cancer", "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Bladder Cancer", "Metastatic Urothelial Carcinoma", "Locally Advanced Solid Tumor", "Neoplasms", "Neoplasm Metastasis", "Neoplasm Malignant", "Neoplasm, Bladder", "Urothelial Neoplasm", "Neoplasm, Urinary Bladder", "Bladder Neoplasm", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "IK-175", "type": "DRUG" }, { "name": "IK-175 and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-12-18", "completion_date": "2023-07-18", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04200963" }, { "nct_id": "NCT00159432", "title": "Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2005-02", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-07-29", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00159432" }, { "nct_id": "NCT00162110", "title": "A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucinous Gastrointestinal Adenocarcinoma" ], "interventions": [ { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-11", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 2, "location_summary": "New York, New York • Cincinnati, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00162110" }, { "nct_id": "NCT00381810", "title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 31, "start_date": "2006-06-22", "completion_date": "2012-02-29", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 11, "location_summary": "Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "San Leandro", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381810" }, { "nct_id": "NCT04833855", "title": "Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Tezepelumab Dose 1", "type": "BIOLOGICAL" }, { "name": "Tezepelumab Dose 2", "type": "BIOLOGICAL" }, { "name": "Omalizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 183, "start_date": "2021-04-15", "completion_date": "2023-04-13", "has_results": true, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Laguna Niguel", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04833855" }, { "nct_id": "NCT00004255", "title": "Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Chimeric Therapies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 15, "location_summary": "La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004255" }, { "nct_id": "NCT07271355", "title": "Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Appendix Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Malignant Neoplasm in the Peritoneum", "Stage IV Appendix Carcinoma AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Unresectable Colorectal Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2026-10-01", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 5, "location_summary": "Goodyear, Arizona • Duarte, California • Irvine, California + 2 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07271355" }, { "nct_id": "NCT00091026", "title": "Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2004-07", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2014-05-15", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091026" }, { "nct_id": "NCT01400685", "title": "Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 34, "start_date": "2012-12", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2018-01-25", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400685" }, { "nct_id": "NCT03430791", "title": "Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Nivolumab 240 mg IV", "type": "DRUG" }, { "name": "Nivolumab 3 mg/kg", "type": "DRUG" }, { "name": "Ipilimumab 1 mg/kg", "type": "DRUG" }, { "name": "NovoTTF200A (Optune)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-12-05", "completion_date": "2021-01-27", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-20T09:53:51.357Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03430791" } ] }